Background: Conversion of standard-release tacrolimus to prolonged-release once-daily tacrolimus is often performed in a 1:1 (mg:mg) manner. We sought to determine the safety and efficacy of this conversion strategy in Chinese renal transplant recipients. Methods: In this single-center study, 16 stable renal transplant recipients were observed for 1 year after a milligram to milligram switch from standard-release to prolonged-release tacrolimus formulation. Trough blood tacrolimus level and graft function were serially monitored. Results: Mean daily dose of tacrolimus was 0.040 ± 0.018 mg/kg before conversion. After conversion, we observed a significant decrease in trough tacrolimus levels, from 4.5 ± 2.2 ng/mL to 3.4 ± 1.1 ng/mL (p = 0.046) at 1 month, and from 4.5 ± 2.2 ng/mL to 3.3 ± 1.1 ng/mL (p = 0.01) at 12 months. After 12 months, 44% of patients (n = 7) experienced a decrease in tacrolimus blood levels of more than 20%. All patients maintained stable graft function otherwise, without acute rejection. Conclusion: Our findings confirm that trough tacrolimus blood level can decrease following a 1:1 (mg:mg) conversion from standard-release to prolonged-release tacrolimus formulation in Chinese patients. Close monitoring of the drug levels and clinical condition seems to be warranted after medication switch. © 2011, Hong Kong Society of Nephrology Ltd. Published by Elsevier Taiwan LLC. All rights reserved.
Pang, W. F., Chow, K. M., Kwan, B. C. H., Kwong, V. W. K., Szeto, C. C., Leung, C. B., & Li, P. K. T. (2011). Clinical experience of conversion from twice-daily standard-release tacrolimus to once-daily prolonged-release tacrolimus in stable renal transplant recipients. Hong Kong Journal of Nephrology, 13(2), 64–67. https://doi.org/10.1016/j.hkjn.2011.09.007